Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Eisai Gets Fast Track for Eribulin | Contract Pharma

What are you searching for?

Sign in
Breaking News, Trials & Filings

Eisai Gets Fast Track for Eribulin

Breast cancer drug to get accelerated review from FDA

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

The FDA has granted Fast Track Status for the NDA of Eribulin, Eisai’s treatment for patients with locally advanced or metastatic breast cancer previously treated with at least two chemotherapy regimens, including an anthracycline and a taxane.

Eisai submitted simultaneous regulatory applications for the approval of eribulin in the U.S., Japan and the European Union (EU) on March 30, 2010. The company also has submitted regulatory applications for approval to health authorities in Switzerland and Singapore. Fast Track status should cut the review process from 10 months to six.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters